Esperion Therapeutics, Inc.
ESPR
$1.50
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 114.30% | 52.00% | 186.33% | 466.14% | 71.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.30% | 52.00% | 186.33% | 466.14% | 71.38% |
| Cost of Revenue | 25.40% | -2.05% | -6.28% | -45.44% | -21.51% |
| Gross Profit | 963.65% | 319.64% | 1,609.00% | 710.87% | 116.63% |
| SG&A Expenses | -18.71% | 20.26% | 30.11% | 40.42% | 88.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.45% | 10.01% | 13.38% | -10.24% | 21.66% |
| Operating Income | 89.57% | 41.79% | 106.96% | 248.69% | 0.34% |
| Income Before Tax | 62.16% | 28.43% | -24.01% | 198.87% | -1.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 62.16% | 28.43% | -24.01% | 198.87% | -1.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.16% | 28.43% | -24.01% | 198.87% | -1.54% |
| EBIT | 89.57% | 41.79% | 106.96% | 248.69% | 0.34% |
| EBITDA | 89.63% | 41.83% | 106.98% | 249.02% | 0.14% |
| EPS Basic | 78.26% | 58.91% | 28.24% | 145.82% | 33.61% |
| Normalized Basic EPS | 79.96% | 58.92% | 89.90% | 145.56% | 33.92% |
| EPS Diluted | 78.26% | 58.91% | 28.24% | 142.49% | 33.61% |
| Normalized Diluted EPS | 79.96% | 58.92% | 89.90% | 140.67% | 33.92% |
| Average Basic Shares Outstanding | 73.99% | 74.25% | 72.82% | 115.78% | 52.96% |
| Average Diluted Shares Outstanding | 73.99% | 74.25% | 72.82% | 141.77% | 52.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
